The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection.
For patients with moderate-to-severe plaque psoriasis, the interleukin-23-receptor antagonist peptide JNJ-77242113 shows greater efficacy than placebo, according to a study published in the Feb. 8 ...
In a trial involving 255 patients with moderate-to-severe plaque psoriasis, the oral interleukin-23–receptor antagonist peptide JNJ-77242113 showed a dose–response relationship and greater efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback